Browsing by Author "Corral, Sebastián"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review
    (2021) Nieto, Rodrigo; Carrasco, Andrea; Corral, Sebastián; Castillo, Rolando; Bustamante, Leonor; Pablo, Gaspar; Silva, Hernán
    Brain Derived Neurotrophic Factor (BDNF) has been linked to cognitive symptoms of schizophrenia, which has been documented in previous reviews by several authors. However, a trend has recently emerged in this field moving from studying schizophrenia as a disease to studying psychosis as a group. This review article focuses on recent BDNF studies in relation to cognition in human subjects during different stages of the psychotic process, including subjects at high risk of developing psychosis, patients at their first episode of psychosis, and patients with chronic schizophrenia. We aim to provide an update of BDNF as a biomarker of cognitive function on human subjects with schizophrenia or earlier stages of psychosis, covering new trends, controversies, current research gaps, and suggest potential future developments in the field. We found that most of current research regarding BDNF and cognitive symptoms in psychosis is done around schizophrenia as a disease. Therefore, it is necessary to expand the study of the relationship between BDNF and cognitive symptoms to psychotic illnesses of different stages and origins.
  • Thumbnail Image
    Publication
    Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample
    (2025) Allott, Kelly; Yassin, Walid; Alameda, Luis; Billah, Tashrif; Borders, Owen; Buccilli, Kate; Carrión, Ricardo E.; Castillo-Passi, Rolando I.; Cho, Kang Ik K.; Chin, Kota; Coleman, Michael J.; Colton, Beau-Luke; Corral, Sebastián; Dwyer, Dominic; Gundersen, Kristina Ballestad; Gur, Ruben C.; Hoftman, Gil D.; Jacobs, Grace R.; Kelly, Sinead; Lewandowski, Kathryn E.; Marcy, Patricia J.; Matneja, Priya; McLaughlin, Danielle; Nunez, Angela R.; Parsa, Setari; Penzel, Nora; Ray, Susan; Reinen, Jenna M.; Ruparel, Kosha; Sand, Michael S.; Santorelli, Gennarina; Seitz-Holland, Johanna; Spark, Jessica; Tamayo, Zailyn; Thompson, Andrew; Tod, Sophie; Wannan, Cassandra M. J.; Wickham, Alana; Wood, Stephen J.; Zoupou, Eirini
    Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years. Watch Dr. Kelly Allott and Dr. William S. Stone discuss their work and this article: https://vimeo.com/1023396087.

Implementado por OpenGeek Services